Find Academic Supervisors

• Clinical Toxicology
• Pharmacoepidemiology
• Poisoning
• +3 more

Professor Nicholas Buckley is a leading academic in Clinical Pharmacology at the University of Sydney and holds a Visiting Professor position at the University of Peradeniya, Sri Lanka. He serves as Research Director for the South Asian Clinical Toxicology Research Collaboration (SACTRC) and is a Consultant Clinical Pharmacologist & Toxicologist at the NSW Poisons Information Centre and Royal Prince Alfred Hospital. His work focuses on improving clinical toxicology practices, poison control policies, and understanding mechanisms of drug toxicity. Co-founder of SACTRC for agrochemical poisoning and snakebite research Chair of Australian Therapeutic Guidelines - Toxicology writing group Editorial roles in Clinical Toxicology, Drug Safety, and Australian Prescriber Research Interests include toxicovigilance, epidemiology of poisoning, acute kidney injury in poisoning/snakebite, pesticide safety interventions, antidote development, and pharmacoepidemiology of psychotropic drugs. His work combines clinical trials, population surveillance, and translational research. Scientific Contributions span 440+ peer-reviewed articles and 22 book chapters, with continuous funding since 2002. He has supervised over 20 higher degree students and leads international collaborations in low-and-middle-income countries through NIHR RIGHT4. Key Affiliations : Member of Charles Perkins Centre, Australian Medicines Handbook Editorial Advisory Board, and NIHR RIGHT4 programme.

• Molecular Structure and Self-Assembly
• Protein Folding and Misfolding
• Amyloid Fibril Formation
• +7 more

Ehud Gazit is a distinguished Professor in the Department of Molecular Microbiology and Biotechnology at Tel Aviv University's Faculty of Life Sciences. He holds the Chair for Nano-Biology and serves as Vice President for Research and Development at Tel Aviv University. Professor Gazit has held numerous prestigious visiting appointments including at Umeå University, Fudan University, and Cambridge University. His academic journey began with a B.Sc. (summa cum laude) from Tel Aviv University's Special University Program for Outstanding Students in 1991, followed by a Ph.D. (with distinction) from the Weizmann Institute of Science in 1997, and postdoctoral training at MIT from 1997-2000. Professor Gazit's research focuses on molecular structure and self-assembly at the nano-scale, particularly examining protein folding, unfolding, and misfolding phenomena. His laboratory investigates the mechanisms and significance of protein unfolding and misfolding, with experimental systems including bacterial toxin-antidote systems, type II diabetes-related amyloidogenic proteins, and the VHL tumor suppressor protein. His work bridges fundamental biochemistry with nanotechnology applications, exploring how molecular self-assembly can be harnessed for technological innovation. His recent publications demonstrate a strong trajectory in peptide-based nanomaterials, with particular emphasis on amyloid formation mechanisms, peptide self-assembly for functional materials, and therapeutic applications targeting neurodegenerative diseases. His work spans multiple disciplines including biochemistry, nanotechnology, materials science, and biomedical engineering, showing increasing integration of fundamental research with practical applications. Professor Gazit has received numerous prestigious awards including: 2020 Landau Prize in Sciences and Arts in the Field of Healthy Aging 2019 Rappaport Prize for Excellence in Biomedical Research 2018 Foreign Fellow of the National Academy of Sciences, India 2016 ERC Advanced Grant from the European Research Council 2015 Elected Member of the European Molecular Biology Organization (EMBO) Professor Gazit has been actively involved in mentoring students and researchers, as evidenced by his extensive publication record with numerous collaborators. He has secured significant research funding including an ERC Advanced Grant. His professional activities include editorial board memberships for journals including Journal of Peptide Science, Nanoscience & Nanotechnology - Asia, and Amyloid. He previously served as Chief Scientist of the Ministry of Science and Technology (2012-2014). His laboratory has developed innovative approaches to studying molecular self-assembly, with particular expertise in peptide nanostructures. The research team has made significant contributions to understanding amyloid formation mechanisms while simultaneously developing novel biomaterials with applications ranging from electronics to medicine. They have established strong collaborations with research groups worldwide, creating a dynamic interdisciplinary research environment focused on the intersection of biology and nanotechnology.

Theodore C BaniaView profile

Assistant Professor

• Medical Toxicology
• HIV/AIDS Research
• Substance Use Disorders
• +4 more

Theodore C Bania, MD, is an Assistant Professor of Emergency Medicine at the Icahn School of Medicine at Mount Sinai, holding multiple leadership roles including Associate Dean for Human Subjects Research Protection, IRB Chair, and Director of Medical Toxicology at Mount Sinai West and Morningside. He specializes in emergency medicine and medical toxicology, with a focus on lipid resuscitation therapy for drug toxicity and HIV education via mobile devices. Education: MD from SUNY Downstate Health Sciences University, fellowship in Medical Toxicology at NYU, and a Master of Science in Clinical Research from Albert Einstein College of Medicine. Research interests include cardiovascular drug toxicity, chemical warfare agents, substance abuse education, and research ethics. His work has led to advancements in lipid therapy models and HIV/HCV education strategies. He has received NIH/NIDA grants and holds the 2010 Super Doctor award. He oversees over 25 years of research at Mount Sinai’s emergency departments and chairs institutional review boards. His publications span toxicology, bioethics, and clinical practices.

• Computational Chemistry
• Artificial Intelligence in Chemistry
• Molecular Modeling
• +6 more

Professor Neil Berry is a distinguished academic and researcher in the Department of Chemistry at the University of Liverpool's School of Physical Sciences. He currently serves as Head of Department (2018-2024) and has held various significant administrative roles including Director of Post Graduate Research for the School of Physical Sciences (2015-2018) and Departmental PGR Lead. His academic journey began at Exeter College, University of Oxford where he earned his MChem in Chemistry (1999) followed by a DPhil (2002) under the supervision of Professor Paul Beer. Professor Berry's research expertise spans computational chemistry with a focus on applying AI, machine learning, and molecular modeling to solve complex problems in chemistry. His work primarily centers on four key areas: medicinal chemistry (particularly antimalarial and antiparasitic drug discovery), materials chemistry (including metal-organic frameworks and supramolecular gels), reaction mechanisms, and chemoinformatics. His group adopts a rational approach to research through molecular and material design, integrating computational modeling with experimental validation through close collaborations with the Liverpool School of Tropical Medicine, University of Washington, and industry partners including GSK, Bayer, and Unilever. His publication record demonstrates a strong focus on applying computational methods to drug discovery for neglected tropical diseases and advanced materials science. Recent work shows increasing integration of machine learning techniques across all research areas, with significant contributions to antimalarial drug development, snakebite treatment, and materials science applications. His research consistently bridges computational prediction with experimental validation, demonstrating the practical impact of his work. Treasurer - Royal Society of Chemistry Chemical Information and Computer Applications Group (2021 - present) Invited committee member - Royal Society of Chemistry Chemical Information and Computer Applications Group (2015 - present) Fellow of Higher Education Academy (2012 - present) Member of Royal Society of Chemistry (2005 - present) Referee for journals including Nature Communications, Journal of Medicinal Chemistry, and Journal of Computer Aided Molecular Design As an educator, Professor Berry has supervised numerous PhD students and postdoctoral researchers, with a particular emphasis on integrating computational approaches with experimental chemistry. His teaching innovations include Chemtube3D (web-based interactive 3D simulations of organic reactions), lecture recording systems, and ChemPreLab (a pre-lab interactive tutoring system). His research group operates at the intersection of chemistry, biology, and computer science, securing substantial funding from EPSRC, MRC, Wellcome Trust, and industry partners.

• Health and Medicine History
• Gender and Sexuality Studies
• History of Race and Power
• +7 more

Farren Yero is an Assistant Professor in the History Department at Lehigh University's College of Arts and Sciences, where she specializes in the history of health, medicine, and gender with a focus on Latin America and the Caribbean. Her interdisciplinary scholarship bridges medical history, gender studies, and Atlantic world history, examining how race, gender, and power have shaped health experiences and medical practices in the early modern period. Dr. Yero received her Ph.D. in History and Gender, Sexuality and Feminist Studies from Duke University in 2020, an M.A. in History from Duke University in 2016, an M.A. in Latin American Studies from Tulane University in 2013, and a B.A. in Anthropology from the University of Florida in 2010. Her academic journey began with archaeological work at the Kingsley Plantation in Jacksonville, Florida, which shaped her interest in Atlantic history and the transatlantic slave trade. Yero's research focuses on health disparities, care practices, and disease experiences in the early modern Atlantic world, with particular attention to smallpox vaccination history. Her current book project, Atlantic Antidote: Race, Gender, and the Birth of the First Vaccine , explores racial and gendered intersections of labor, childrearing, and disease prevention in the Spanish Americas. She is also developing a history of the Caribbean's earliest smallpox epidemic (1519) through the life of America's first "patient zero." Her work consistently examines how marginalized communities navigated health challenges within colonial contexts. Her publications reveal a strong emphasis on vaccine history, gender and medicalization, Afro-Caribbean religious practices during epidemics, and the intersections of race, citizenship, and public health. Yero's scholarship demonstrates how medical history provides critical insights into broader social structures, particularly regarding race, gender, and power dynamics in colonial societies. Nineteenth Century Studies Dissertation Award from the Latin American Studies Association (LASA) Richmond Brown Dissertation prize, Honorable Mention, from the Latin American and Caribbean Section of the Southern Historical Association Dr. Yero has received significant research support from the National Endowment for the Humanities, American Council of Learned Societies, Fulbright-Hays program, Andrew W. Mellon Foundation, John Carter Brown Library, Newberry Library, Institute of Advanced Studies in the Humanities at the University of Edinburgh, and Omohundro Institute of Early American History and Culture. She previously held postdoctoral positions at Binghamton University, College of William and Mary, University of Edinburgh, and Duke University. At Lehigh, she teaches courses on health and society in Latin America, gender and medicine, pandemics, and digital/public history methods.

Kazunori KoideView profile

Professor

• Organic Chemistry
• Natural Products Synthesis
• Fluorescent Sensors
• +3 more

Kazunori Koide is a Professor in the Department of Chemistry at the University of Pittsburgh, affiliated with the Dietrich School of Arts and Sciences. His research focuses on organic synthesis of natural products, development of novel synthetic methodologies, and creation of fluorescent probes for biomedical applications. He leads the Koide Group, which explores anticancer compounds like FR901464 and stresgenin B, as well as sensors for metals such as palladium, copper, and platinum. Research interests include total synthesis of bioactive natural products, mechanistic studies of organic reactions, and design of fluorogenic probes for real-time imaging of biomolecules. Notable projects involve Birch reduction optimization, palladium detection technologies, and RNA splicing modulation therapies. His work has led to awards including the University of Pittsburgh Chancellor's Distinguished Research Award (2009) and the Merck Technology Collaboration Award (2014). Key contributions span medicinal chemistry, analytical methods, and drug discovery, with over 100 publications in top journals like J. Am. Chem. Soc. and Nature Catalysis . Lab activities emphasize interdisciplinary approaches, combining organic synthesis with cell biology and materials science. Collaborations with pharmaceutical companies and academic institutions drive translational research in cancer therapy and environmental monitoring.

Donovan C. HainesView profile

Professor

• Bioorganic Chemistry
• Biophysics
• Enzymology
• +5 more

Donovan C. Haines serves as Professor and Chair of the Department of Chemistry at Sam Houston State University within the College of Science & Engineering Technology. His extensive academic career includes previous positions as Assistant Professor and Associate Professor at both the University of Texas at Dallas and Sam Houston State University, culminating in his current professorship and chairmanship since 2020. Haines' research spans multiple interconnected fields focusing on the structure and mechanism of monooxygenase systems, particularly cytochrome P450 enzymes involved in metabolism of natural products, neurotransmitters, drugs, and hormones. His work has direct medical relevance to neurodegenerative diseases including ALS, Parkinson's, and Alzheimer's. Specific research areas include bacterial quorum sensing, forensic chemistry related to human decomposition, and lipid metabolism enzymes connected to immune function and skin disorders. Analysis of his 15 most recent publications reveals a strong focus on cytochrome P450 enzymology, with significant work on bacterial quorum sensing mechanisms, forensic applications, and protein structure-function relationships. His research demonstrates consistent interdisciplinary collaboration across biochemistry, microbiology, and forensic science. Haines maintains an active research program with publications spanning over two decades, with his most recent work expanding into aerospace medicine with research on remains containment in low-earth orbit. His scientific contributions demonstrate both depth in specialized enzymology and breadth across multiple application domains. As an educator, Haines teaches across the chemistry curriculum from introductory courses to advanced biochemistry, demonstrating commitment to both undergraduate and graduate education. His laboratory employs diverse methodologies including organic synthesis, biochemistry, molecular biology, and biophysics to study enzyme mechanisms.

Valery FokinView profile

Professor

• Organic Chemistry
• Chemical Biology
• Drug Discovery
• +5 more

Valery Fokin is a Professor of Chemistry at the University of Southern California (USC), Department of Chemistry. His research focuses on organic synthesis with applications in chemical biology, particularly in click chemistry, antidote development, and bioconjugation. He holds a Ph.D. from USC (1998) and has contributed extensively to the design of novel synthetic methods and bioactive molecules. His work spans drug discovery, catalysis, and the development of reagents for toxicology applications. Notable contributions include advancements in azide-alkyne cycloaddition (CuAAC) and sulfur fluoride exchange (SuFEx) reactions, which have broad implications in medicinal chemistry and materials science. His lab explores strategies to create efficient organophosphate antidotes and antimicrobial agents targeting drug-resistant pathogens. Publications highlight innovations in microdroplet chemistry, enzyme reactivation mechanisms, and the synthesis of heterocyclic compounds. Fokin’s research bridges academic and industrial collaboration, as seen in studies on cannabinoid-derived drug potential and scalable synthesis methods. His team actively pursues applications in drug delivery and tissue-specific targeting. While no specific awards or grants are listed, his prolific publication record reflects sustained contributions to chemical biology. His advising and lab activities emphasize interdisciplinary approaches to solving biomedical challenges through innovative organic synthesis.

Charlene BlakeView profile

Clinical Professor

• Cardiothoracic Anesthesiology
• Aptamer Therapeutics
• Anticoagulation
• +7 more

Charlene Blake, MD, PhD is a Clinical Professor in the Department of Anesthesiology and Perioperative Care at the University of California, San Francisco (UCSF) . She is affiliated with multiple UCSF campuses, including Mission Bay, Mount Zion, and Parnassus, and specializes in Adult Cardiac anesthesiology. Her dual training in medicine and genetics underscores her interdisciplinary approach to research and clinical practice. MD, Medical Scientist Training Program, Duke University School of Medicine (2010) PhD, Genetics and Genomics, Duke University Graduate School (2009) BA, Chemistry, Fisk University (2002) Cardiothoracic Anesthesiology Fellowship, Washington University in St. Louis (2015) Anesthesiology Residency, Washington University in St. Louis (2014) Diversity, Equity, and Inclusion Champion Training, University of California (2018) Dr. Blake's research lies at the intersection of molecular therapeutics and clinical anesthesiology, with a strong focus on RNA aptamers , antidote development , and drug safety . Her work explores the use of aptamers as reversible anticoagulants and their applications in stroke and hemorrhage. She also investigates pharmacogenomics , particularly CYP2D6 and metoprolol metabolism, and is deeply engaged in understanding and addressing ethnic disparities in medical training and inclusive medical technology design . Her publications reflect a dual trajectory: one in translational molecular medicine , focusing on aptamer control and antidote systems, and another in health equity , examining microaggressions, diversity in anesthesiology, and the impact of skin pigmentation on medical devices. This combination highlights her commitment to both scientific innovation and social responsibility in medicine. Development of universal antidotes for aptamer therapeutics Reversible aptamers for stroke and hemorrhage PAI-1-specific aptamers in cancer metastasis Metoprolol pharmacokinetics and CYP2D6 Ethnic disparities in fellowship training Inclusive design of light-based medical devices Dr. Blake is actively involved in advancing diversity and inclusion in academic medicine, having completed formal training in this area and publishing on microaggressions and equity. Her research has been supported by NIH grants (e.g., R01 HL065222, U54 CA119347), and she collaborates with prominent scientists in nucleic acid therapeutics. She advises on clinical and translational research and contributes to policy discussions on equity in medical education and practice. She is affiliated with research teams focused on aptamer-based therapeutics and health equity initiatives at UCSF, working within interdisciplinary labs that bridge molecular biology, anesthesiology, and public health. Her future work is likely to expand on personalized anticoagulation strategies and inclusive medical technologies.

Jeffrey WeitzView profile

Professor

• Thrombosis
• Hemostasis
• Atherosclerosis
• +3 more

Dr. Jeffrey Weitz is a Professor in the Departments of Medicine and Biochemistry and Biomedical Sciences at McMaster University, and serves as Executive Director of the Thrombosis and Atherosclerosis Research Institute (TaARI). He holds prestigious academic titles including the Tier I Canada Research Chair in Thrombosis and the Fraser Mustard Chair in Cardiovascular Research. His research focuses on hemostasis, thrombosis, and anticoagulant therapies, with a particular emphasis on developing safer anticoagulants targeting factor XI and improving medical device biocompatibility. Dr. Weitz leads a multidisciplinary team investigating mechanisms of thrombosis, clot formation regulation, and novel therapies to reduce cardiovascular-related mortality. His work spans translational research, clinical trials, and epidemiological studies, with contributions to understanding polyphosphate's role in coagulation and the development of clot-resistant medical device coatings. TaARI, under his leadership, bridges basic and clinical research to address thrombosis and bleeding disorders. Key achievements include advancements in factor XI inhibition and the design of anti-thrombogenic materials. Research Clusters: Health & Bio-innovation Key Awards: Tier I Canada Research Chair, Fraser Mustard Chair Labs: Weitz Lab (focusing on coagulation mechanisms and anticoagulant development) Dr. Weitz collaborates with bioengineers to innovate biomaterials and devices, while maintaining clinical relevance through anticoagulant trials like AXIOMATIC-TKR and AZALEA-TIMI 71. His lab's recent studies explore histidine-rich glycoprotein's role in clotting regulation and polyphosphate toxicity mitigation.

Félix CarvalhoView profile

Professor

• Toxicology
• Pharmacology
• Drug Safety
• +4 more

Félix Carvalho is a Full Professor of Toxicology at the Faculty of Pharmacy, University of Porto, Portugal. He has held academic positions since 1990, progressing through roles such as Assistant and eventually Full Professor. His research focuses on drug safety, drug abuse mechanisms, and antidote development. He serves as Head of the Toxicology Laboratory and Vice-Director of the Department of Biological Sciences at FFUP. Carvalho is an Editor-in-Chief of Acta Farmacêutica Portuguesa and sits on editorial boards of 15+ journals including Addiction and Pharmacological Research . He has authored over 500 publications and co-edited books on forensic and fundamental toxicology. Awards include the 2011 Santo Tirso Medal of Honour and Numerary Membership in the Portuguese Academy of Pharmaceutical Sciences (2021). He actively participates in national and international organizations like EUROTOX and INFARMED. PharmD, PhD, European Registered Toxicologist (ERT), European Certified Pharmacologist (EuCP) Leadership roles: Past-President of EUROTOX and Portuguese Society of Pharmacology Research interests emphasize mechanistic toxicology with a focus on paraquat, ecstasy (MDMA), and mushroom poisoning. His work bridges fundamental research with clinical applications, including antidote development for acute toxic exposures. Editorial Leadership: Oversees 8+ journals across toxicology, pharmacology, and public health Service: Member of INFARMED's Medicines Evaluation Committee and Portuguese Pharmaceutical Society Labs/Teams: Directs the Toxicology Laboratory at FFUP, coordinating multidisciplinary projects on drug safety and environmental toxins.

Anna MeyerView profile

Assistant Professor

• Machine Learning
• Formal Methods
• Human-Computer Interaction
• +3 more

Anna Meyer is an Assistant Professor in the Computer Science department at Carleton College, where she has been since 2025. She earned her Ph.D. in Computer Science from the University of Wisconsin-Madison, advised by Aws Albarghouthi and Loris D’Antoni, and a B.A. in Mathematics from Carleton College. Before her academic career, she worked as a software developer at Epic in Madison. Her research focuses on improving the trustworthiness of machine learning models by addressing multiplicity—the phenomenon where models with similar performance produce divergent outputs, undermining reliability and fairness. She employs formal methods, machine learning techniques, and human-computer interaction frameworks to analyze and control multiplicity across ML pipelines. Her work has been recognized through publications at top venues like CHI, UAI, FAccT, and NeurIPS, with a workshop paper at ICLR 2024. Anna teaches courses such as CS 251: Programming Languages and CS 320: Machine Learning . Her technical contributions include the AntIDoTe-P repository, which implements abstract interpretation techniques to certify robustness against data bias in decision trees. The codebase supports datasets like COMPAS, Adult Income, and Drug Consumption, with preprocessing documented in Jupyter notebooks.

Matthew R. DentView profile

Assistant Professor

• Protein biochemistry
• Biophysical techniques
• Bioinorganic chemistry
• +4 more

Matthew R. Dent is an Assistant Professor in the Department of Chemistry at Wayne State University’s College of Liberal Arts and Sciences. His research focuses on protein biochemistry, biophysical and bioinorganic techniques, and drug design. He holds a B.S. from James Madison University (2014), a Ph.D. in Chemistry from the University of Wisconsin–Madison (2019), and completed an NIH Postdoctoral Fellowship at the University of Pittsburgh (2019–2024). B.S., James Madison University, 2014 Ph.D. in Chemistry, University of Wisconsin–Madison, 2019 NIH Postdoctoral Research Fellow, University of Pittsburgh, 2019–2024 His research interests center on protein biochemistry, leveraging biophysical and bioinorganic methodologies, chemical computation, and bioinformatics. He investigates animal models of disease and drug design, particularly developing CO-sensing hemoproteins for medical applications and exploring heme-dependent signaling pathways in cellular contexts. Notable grants include NIH K99/R00 awards for optimizing hemoprotein-based CO antidotes and biosensors. His NIH postdoctoral fellowship supported studies on heme proteins and their medical applications. Additional grants focus on oxygen carrier development for hemorrhagic shock resuscitation. Though specific advisees are not listed, his research involves interdisciplinary collaborations. Grants emphasize CO poisoning treatments and oxygen delivery systems. His work bridges biochemistry, pharmacology, and medical applications. Labs or teams are not explicitly detailed in the provided information.

Andrew KingView profile

Assistant Professor

• Medical Toxicology
• Emergency Medicine
• Poison Control
• +5 more

Andrew King is an Assistant Professor at Wayne State University School of Medicine and serves as Medical Toxicology Fellowship Director at Children’s Hospital of Michigan. He holds concurrent appointments as Medical Director of the Michigan Poison & Drug Information Center and Attending Physician at Sinai Grace Hospital, Detroit Receiving Hospital, and Children’s Hospital of Michigan. His clinical practice spans emergency medicine and toxicology. Education: M.D. from Washington University in St. Louis (2004-2008) B.A. from Northwestern University (2000-2004) Emergency Medicine Residency (Chief Resident) at University of Pittsburgh (2008-2011) Medical Toxicology Fellowship at University of Pittsburgh (2011-2013) Research Focus: Dr. King specializes in clinical toxicology with emphasis on poison control, envenomations, organophosphate poisoning, and cardiotoxicology. His work integrates emergency medicine protocols with toxicological interventions for substance overdoses, metabolic toxicities, and environmental exposures. Publication Trends: His 15 most recent articles (2012-2016) predominantly address toxicology case management, including innovative treatments for envenomations, antidotal therapies for poisonings, and diagnostic challenges in drug overdoses. Recurring themes include organophosphate/carbamate toxicity, sympathomimetic syndromes, and metal/chemical exposures. Awards & Honors: Distinguished Teacher of the Year (Sinai Grace/DRH Residency Programs, 2015) MTF Medical Toxicology Practice Award (2013) Resident Clinician of the Year (Pittsburgh, 2011) Alpha Omega Alpha Honor Society (2008) Professional Leadership: As Fellowship Director, he oversees toxicology training programs and advises medical fellows. He chairs committees for the American College of Medical Toxicologists (ACMT) and reviews manuscripts for multiple peer-reviewed journals including Journal of Medical Toxicology . Laboratories & Teams: Directs clinical operations at Michigan Poison & Drug Information Center, coordinating toxicology consultations and research collaborations across Detroit Medical Center hospitals.

Betty ChanView profile

Associate Professor

• Clinical Toxicology
• Emergency Medicine
• Harm Reduction
• +5 more

Associate Professor Betty Chan is an Emergency Physician, Clinical Toxicologist, and clinical researcher at the University of New South Wales. She serves as Head of the Discipline of Critical Care at UNSW and Head of the Clinical Toxicology Unit at the Prince of Wales Hospital. Additionally, she works as a VMO toxicologist at the New South Wales Poisons Information Centre and serves on the editorial board of Clinical Toxicology and the SES LHD Human Research and Ethics Committee. Dr. Chan completed her Emergency Medicine training in 1990 and earned her PhD in toxicology from the University of Sydney in 1997. Her academic credentials include MBBS, FACEM, PhD, and MDiv. Her primary research interests focus on translational research in Clinical Toxicology, Harm Reduction, Antidotes, Medical Education, and the application of Artificial Intelligence in medical education. Specific areas of investigation include digoxin overdose management, dihydropyridine toxicity, methotrexate intoxication and antidotes, safe opioid use and prescription practices, development of clinical decision rules for non-traumatic CT head imaging, herbicide toxicity (including paraquat, bromoxynil, and MCPA), acute behavioral disturbance treatment, sodium channel blocker toxicity, lithium poisoning, cognitive assessment following overdose and shift work, tapentadol prescription trends and poisoning, and adherence to clinical guidelines for specific poisonings. Analysis of Dr. Chan's recent publications reveals a strong focus on clinical toxicology with particular emphasis on drug overdose management, antidote efficacy, and patient safety. Her work spans multiple areas including cardiovascular toxicology (digoxin, calcium channel blockers), hepatotoxicity (acetaminophen), neurotoxicology (anticholinergics, antipsychotics), and harm reduction strategies (naloxone distribution). Many of her studies are part of the Australian Toxicology Monitoring (ATOM) research program, demonstrating her commitment to evidence-based toxicology practice. 2016 John Gilroy Potts Award at the ACEM conference for the paper 'The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioural Disturbance in the Emergency Department' 2019 Best Scientific presentation at the 39th Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) on 'Using EXTRIP criteria as indications for Extracorporeal Treatment in Lithium Poisoning.' As Head of the Discipline of Critical Care at UNSW, Dr. Chan leads the curriculum and teaching for medical students in Emergency Medicine, Anesthesia, and Intensive Care. She also oversees the teaching curriculum and supervision of toxicology registrars and fellows as head of the Clinical Toxicology Unit. Her research supervision includes ILP Honours projects focused on the Poisons Information Centre clinical Toxicology referral Study (PICTS) and adherence to clinical guidelines for specific poisonings. She has been principal investigator for numerous clinical research projects in toxicology, including the multi-center Australian Toxicology Monitoring (ATOM) Study initiated in 2013 and the Translational Australian Clinical Toxicology (TACT) program funded by NHMRC grants. Dr. Chan's work has significantly impacted clinical practice, particularly in demonstrating that patients with digoxin poisoning can be managed safely with small, titrated doses of digoxin antibody, and establishing guidelines for folinic acid use in methotrexate poisoning. Her research on cognitive impairment following sedative overdose has informed recommendations about post-overdose activity restrictions.